IL320856A - Pharmaceutical combinations and uses thereof - Google Patents

Pharmaceutical combinations and uses thereof

Info

Publication number
IL320856A
IL320856A IL320856A IL32085625A IL320856A IL 320856 A IL320856 A IL 320856A IL 320856 A IL320856 A IL 320856A IL 32085625 A IL32085625 A IL 32085625A IL 320856 A IL320856 A IL 320856A
Authority
IL
Israel
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
IL320856A
Other languages
Hebrew (he)
Inventor
Marta Cortes-Cros
Stephane Ferretti
Jacques Hamon
Juergen Hans-Hermann Hinrichs
Isabel Cristina Jaco
Sandra Blum-Kallert
Laurent Laborde
Henrik Moebitz
Joseph Schoepfer
Ross Strang
Kanter Ruben De
Rita Andraos-Rey
Michele Moschetta
Original Assignee
Novartis Ag
Cortes Cros Marta
Stephane Ferretti
Jacques Hamon
Hinrichs Juergen Hans Hermann
Isabel Cristina Jaco
Blum Kallert Sandra
Laurent Laborde
Henrik Moebitz
Joseph Schoepfer
Ross Strang
Kanter Ruben De
Andraos Rey Rita
Michele Moschetta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Cortes Cros Marta, Stephane Ferretti, Jacques Hamon, Hinrichs Juergen Hans Hermann, Isabel Cristina Jaco, Blum Kallert Sandra, Laurent Laborde, Henrik Moebitz, Joseph Schoepfer, Ross Strang, Kanter Ruben De, Andraos Rey Rita, Michele Moschetta filed Critical Novartis Ag
Publication of IL320856A publication Critical patent/IL320856A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL320856A 2022-11-18 2023-11-16 Pharmaceutical combinations and uses thereof IL320856A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263384313P 2022-11-18 2022-11-18
US202363486206P 2023-02-21 2023-02-21
US202363508015P 2023-06-14 2023-06-14
US202363582920P 2023-09-15 2023-09-15
PCT/IB2023/061593 WO2024105610A1 (en) 2022-11-18 2023-11-16 Pharmaceutical combinations and uses thereof

Publications (1)

Publication Number Publication Date
IL320856A true IL320856A (en) 2025-07-01

Family

ID=88874699

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320856A IL320856A (en) 2022-11-18 2023-11-16 Pharmaceutical combinations and uses thereof

Country Status (10)

Country Link
US (1) US20240197715A1 (en)
EP (1) EP4618991A1 (en)
JP (1) JP2025537787A (en)
KR (1) KR20250099749A (en)
CN (1) CN120225197A (en)
AU (1) AU2023380159A1 (en)
IL (1) IL320856A (en)
MX (1) MX2025005792A (en)
TW (1) TW202421158A (en)
WO (1) WO2024105610A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY40470A (en) * 2022-10-12 2024-05-15 Novartis Ag TRICYCLIC COMPOUNDS AND THEIR USES
WO2024193683A1 (en) * 2023-03-23 2024-09-26 Danatlas Pharmaceuticals Co., Ltd. Bicyclic derivatives, compositions and uses thereof
CN118684688A (en) * 2023-03-24 2024-09-24 上海济煜医药科技有限公司 A class of heterocyclic compounds as WRN helicase inhibitors and preparation methods and applications thereof
AU2024286830A1 (en) 2023-06-08 2025-12-04 Nimbus Wadjet, Inc. Wrn inhibitors
WO2024255765A1 (en) * 2023-06-12 2024-12-19 Nuphase Therapeutics (Hangzhou) Limited., Co. Novel compounds, compositions comprising the same and uses thereof
CN121419979A (en) * 2023-06-13 2026-01-27 林伯士瓦吉特公司 Thiazolidine-7(4H)-one WRN inhibitor
WO2024255790A1 (en) * 2023-06-15 2024-12-19 勤浩医药(苏州)有限公司 Fused ring compounds, pharmaceutical composition comprising same and use thereof
WO2025021148A1 (en) * 2023-07-27 2025-01-30 贝达药业股份有限公司 Wrn inhibitor, and pharmaceutical composition thereof and use thereof
JPWO2025058000A1 (en) 2023-09-13 2025-03-20
TW202547484A (en) * 2024-04-10 2025-12-16 瑞士商諾華公司 Pharmaceutical combinations and uses thereof
CN118994353A (en) * 2024-07-09 2024-11-22 云南大学 Molecular switch and inhibitor for controlling conversion of colorectal cancer cell genome from MSS to MSI and application thereof
WO2026108891A1 (en) * 2024-11-20 2026-05-28 Insilico Medicine Ip Limited Combination comprising a wrn inhibitor and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2017058716A1 (en) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
EP4085919A3 (en) * 2017-07-21 2023-02-08 Novartis AG Compositions and methods to treat cancer
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. Benzosulfonyl compounds
WO2019113236A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
WO2019236448A1 (en) * 2018-06-04 2019-12-12 The Broad Institute, Inc. Therapeutic treatment of microsatellite unstable cancers
EP3806850A2 (en) 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Methods of inhibiting proliferative cells
US20210171958A1 (en) * 2018-08-23 2021-06-10 Foghorn Therapeutics Inc. Methods of treating cancer
EP3877356A4 (en) 2018-11-09 2022-06-22 Vivace Therapeutics, Inc. Bicyclic compounds
AU2020257207B2 (en) 2019-04-16 2026-06-04 Vivace Therapeutics, Inc. Bicyclic compounds
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (en) 2019-05-31 2022-03-22 Ikena Oncology Inc Tead inhibitors and uses thereof
CN115279368B (en) 2019-11-20 2024-05-24 维瓦斯治疗公司 Heteroaryl compounds
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
WO2021146266A1 (en) * 2020-01-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods and compositions for cancer immunotherapy
TWI894229B (en) 2020-03-16 2025-08-21 瑞士商諾華公司 Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors
KR20230065317A (en) 2020-09-09 2023-05-11 케이제이 케미칼즈 가부시키가이샤 Solvent for resin synthesis and method for producing synthetic resin using the solvent
US20240025913A1 (en) 2020-10-21 2024-01-25 Vivace Therapeutics, Inc. Tertiary carboxamide compounds
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
BR112023014751A2 (en) 2021-01-25 2023-10-03 Ikena Oncology Inc COMBINATION OF A 3-(IMIDAZOLE-4-IL)-4-(AMINO)-BENZENOSULFONAMIDE TEAD INHIBITOR WITH AN EGFR INHIBITOR AND/OR MEK INHIBITOR FOR USE IN THE TREATMENT OF LUNG CANCER
AR125966A1 (en) 2021-05-26 2023-08-30 Novartis Ag NEW BICYCLIC COMPOUNDS AND THEIR USES
WO2023062575A1 (en) 2021-10-14 2023-04-20 Ideaya Biosciences, Inc. Cyclic vinyl sulfone compounds as wrn inhibitors

Also Published As

Publication number Publication date
TW202421158A (en) 2024-06-01
MX2025005792A (en) 2025-06-02
CN120225197A (en) 2025-06-27
WO2024105610A1 (en) 2024-05-23
JP2025537787A (en) 2025-11-20
KR20250099749A (en) 2025-07-02
AU2023380159A1 (en) 2025-05-15
US20240197715A1 (en) 2024-06-20
EP4618991A1 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
EP4215208A4 (en) Pharmaceutical combination and use thereof
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
EP3706741A4 (en) Pharmaceutical composition and use thereof
GB202002010D0 (en) Microtopographies and uses thereof
SI3981390T1 (en) Lacosamide pharmaceutical composition and pharmaceutical preparation thereof
IL275899A (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
IL313171A (en) Il10 variants and uses thereof
GB202414054D0 (en) Bioactives and their uses
EP4140480A4 (en) Drug combination and use thereof
EP3999056A4 (en) Pharmaceutical combination and use thereof
IL319382A (en) Pharmaceutical composition and use thereof
GB202004832D0 (en) Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
EP4342492A4 (en) Pharmaceutical combination and use thereof
EP4364735A4 (en) Pharmaceutical composition and use thereof
EP4129282A4 (en) Pharmaceutical combination and use thereof
IL292646A (en) Pharmaceutical combination and use thereof
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
CA3270902A1 (en) Pharmaceutical combinations and uses thereof
HK40124257A (en) Pharmaceutical combinations and uses thereof
CA3273324A1 (en) Pharmaceutical combinations and uses thereof
AU2022903599A0 (en) Pharmaceutical combinations and uses thereof
HK40103610A (en) Pharmaceutical combination and use thereof
HK40081165A (en) Pharmaceutical combination comprising tno155 and nazartinib
IL327411A (en) Pharmaceutical compositions comprising maralixibat and uses thereof
HK40099664A (en) Pharmaceutical composition and use thereof